Open Access

Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19 (Review)

  • Authors:
    • Liliana Baroiu
    • Lucreția Anghel
    • Alin Laurențiu Tatu
    • Alina Viorica Iancu
    • Caterina Dumitru
    • Ana-Cristina Leșe
    • Miruna Drăgănescu
    • Florentina Năstase
    • Elena Niculeț
    • Silvia Fotea
    • Aurel Nechita
    • Doina Carina Voinescu
    • Anca Ioana Stefanopol
  • View Affiliations

  • Published online on: April 12, 2022     https://doi.org/10.3892/etm.2022.11312
  • Article Number: 385
  • Copyright: © Baroiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The cytokine storm from the evolution of severe cases of COVID‑19, requiring strong immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) infections in these patients. An analysis of the first observational studies in patients with COVID‑19 and immunosuppressive therapy and HBV infection along with special clinical cases was presented, as well as personal experience on a series of cases (a group of 958 patients with COVID‑19), compared with the analysis of studies performed on patients with HBV infection that underwent biological therapies for psoriasis and personal experience (a group of 81 psoriasis patients treated with biological therapies). Clinical studies have revealed that HBV reactivation in patients undergoing biological therapies for psoriasis, can be prevented with monitoring and treatment protocols and thus, these therapies have been demonstrated to be safe and effective. In COVID‑19, immunosuppressive therapies are short‑lived but in high doses, and the conclusions of clinical trials are contradictory, but there are published cases of HBV reactivation, which requires a unitary attitude in the prevention of HBV reactivation in these patients. An algorithm was presented for monitoring and treatment of HBV infection for patients with psoriasis treated with biological therapy and the conditions when this protocol can be used for patients with COVID‑19 and immunosuppressive therapy.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Baroiu L, Anghel L, Tatu AL, Iancu AV, Dumitru C, Leșe A, Drăgănescu M, Năstase F, Niculeț E, Fotea S, Fotea S, et al: Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19 (Review). Exp Ther Med 23: 385, 2022.
APA
Baroiu, L., Anghel, L., Tatu, A.L., Iancu, A.V., Dumitru, C., Leșe, A. ... Stefanopol, A.I. (2022). Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19 (Review). Experimental and Therapeutic Medicine, 23, 385. https://doi.org/10.3892/etm.2022.11312
MLA
Baroiu, L., Anghel, L., Tatu, A. L., Iancu, A. V., Dumitru, C., Leșe, A., Drăgănescu, M., Năstase, F., Niculeț, E., Fotea, S., Nechita, A., Voinescu, D. C., Stefanopol, A. I."Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19 (Review)". Experimental and Therapeutic Medicine 23.6 (2022): 385.
Chicago
Baroiu, L., Anghel, L., Tatu, A. L., Iancu, A. V., Dumitru, C., Leșe, A., Drăgănescu, M., Năstase, F., Niculeț, E., Fotea, S., Nechita, A., Voinescu, D. C., Stefanopol, A. I."Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19 (Review)". Experimental and Therapeutic Medicine 23, no. 6 (2022): 385. https://doi.org/10.3892/etm.2022.11312